60th Annual Meeting of the Italian Cancer Society
Care and cure of cancer patients: bridging basic research into clinical setting

Milan, 19 - 22 September 2018
Università degli Studi
Via Festa del Perdono, 7

Final program
Auspices

Under the auspices of:

PATROCINIO
Comune di
Milano

Associazione Italiana di Oncologia Medica

Supported by:

AIRC
Fondazione Zegna

Rendiamo il cancro sempre più curabile.
Committees

SCIENTIFIC COORDINATOR
Gabriella Sozzi (IRCCS National Cancer Institute, Milan, Italy)

LOCAL SCIENTIFIC AND ORGANIZING COMMITTEE
Giovanni Apolone (Scientific Director, IRCCS National Cancer Institute, Milan, Italy)
Andrea Anichini (IRCCS National Cancer Institute, Milan, Italy)
Mario Colombo (IRCCS National Cancer Institute, Milan, Italy)
Filippo De Braud (IRCCS National Cancer Institute, Milan, Italy)
Massimo Di Nicola (IRCCS National Cancer Institute, Milan, Italy)
Andrea Ferrari (IRCCS National Cancer Institute, Milan, Italy)
Marina Garassino (IRCCS National Cancer Institute, Milan, Italy)
Marilena Iorio (IRCCS National Cancer Institute, Milan, Italy)
Delia Mezzanzanica (IRCCS National Cancer Institute, Milan, Italy)
Ugo Pastorino (IRCCS National Cancer Institute, Milan, Italy)
Filippo Pietrantonio (IRCCS National Cancer Institute, Milan, Italy)
Luca Roz (IRCCS National Cancer Institute, Milan, Italy)
Elda Tagliabue (IRCCS National Cancer Institute, Milan, Italy)

SIC SCIENTIFIC BOARD
President
Gabriella Sozzi (IRCCS National Cancer Institute, Milan, Italy)

President Elect
Nicola Normanno (National Cancer Institute “G. Pascale”, Naples, Italy)

Board
Paola Chiarugi (University of Florence, Italy)
Amedeo Columbano (University of Cagliari, Italy)
Rita Falcioni (Regina Elena National Cancer Institute, Rome, Italy)
Davide Melisi (University of Verona, Italy)
Katia Scotlandi (IRCCS Orthopaedic Rizzoli Institute, Bologna, Italy)
Elda Tagliabue (IRCCS National Cancer Institute, Milan, Italy)
Giulia Taraboletti (“Mario Negri” Institute for Pharmacological Research, Bergamo, Italy)

Members under 35
Antonino Bruno (MultiMedica, Milan, Italy)
Marco Macagno (University of Turin, Italy)
Past President
Silvia Giordano (University of Turin, Italy)

SIC Secretariat
Società Italiana di Cancerologia
Via G. Venezian, 1
20133 Milano MI
E-mail: sic@istitutotumori.mi.it
www.cancerologia.it

Organizing Secretariat
adriacongrex
Via Sassonia, 30
47922 Rimini RN
E-mail: sic2018@adriacongrex.it
www.adriacongrex.it
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adriana Albini</td>
<td>MultiMedica, Milan, Italy</td>
</tr>
<tr>
<td>Andrea Anichini</td>
<td>IRCCS National Cancer Institute, Milan, Italy</td>
</tr>
<tr>
<td>Alberto Bardelli</td>
<td>University of Turin, Italy</td>
</tr>
<tr>
<td>Tommaso Balestra</td>
<td>IRCCS Orthopaedic Rizzoli Institute, Bologna, Italy</td>
</tr>
<tr>
<td>Anne-Lise Borresen-Dale</td>
<td>University Hospital The Norwegian, Oslo, Norway</td>
</tr>
<tr>
<td>Gerard Brady</td>
<td>Cancer Research UK Manchester Institute, Manchester, United Kingdom</td>
</tr>
<tr>
<td>Antonino Bruno</td>
<td>MultiMedica, Milan, Italy</td>
</tr>
<tr>
<td>Paola Chiarugi</td>
<td>University of Florence, Italy</td>
</tr>
<tr>
<td>Mario Paolo Colombo</td>
<td>IRCCS National Cancer Institute, Milan, Italy</td>
</tr>
<tr>
<td>Amedeo Columbano</td>
<td>University of Cagliari, Italy</td>
</tr>
<tr>
<td>Filippo De Braud</td>
<td>IRCCS National Cancer Institute, Milan, Italy</td>
</tr>
<tr>
<td>Giannino Del Sal</td>
<td>University of Trieste, Italy</td>
</tr>
<tr>
<td>Serena Di Cosimo</td>
<td>IRCCS National Cancer Institute, Milan, Italy</td>
</tr>
<tr>
<td>Rodrigo Dienstmann</td>
<td>Vall d’Hebron Institute of Oncology, Barcelona, Spain</td>
</tr>
<tr>
<td>Massimo Di Nicola</td>
<td>IRCCS National Cancer Institute, Milan, Italy</td>
</tr>
<tr>
<td>Rita Falcioni</td>
<td>Regina Elena National Cancer Institute, Rome, Italy</td>
</tr>
<tr>
<td>Federica Fusella</td>
<td>University of Turin, Italy</td>
</tr>
<tr>
<td>Marina Garassino</td>
<td>IRCCS National Cancer Institute, Milan, Italy</td>
</tr>
<tr>
<td>Cyrus Ghajar</td>
<td>Fred Hutchinson Cancer Research Center, Seattle WA, USA</td>
</tr>
<tr>
<td>Luca Gianni</td>
<td>IRCCS San Raffaele Hospital, Milan, Italy</td>
</tr>
<tr>
<td>Silvia Giordano</td>
<td>University of Turin, Italy</td>
</tr>
<tr>
<td>Douglas Hanahan</td>
<td>EPFL, École Polytechnique Fédérale de Lausanne, Switzerland</td>
</tr>
<tr>
<td>Marilena Valeria Iorio</td>
<td>IRCCS National Cancer Institute, Milan, Italy</td>
</tr>
<tr>
<td>Franco Locatelli</td>
<td>Bambino Gesù Hospital, Rome, Italy</td>
</tr>
<tr>
<td>Domenica Lorusso</td>
<td>IRCCS National Cancer Institute, Milan, Italy</td>
</tr>
<tr>
<td>Marco Macagno</td>
<td>Candiolo Cancer Institute, Turin, Italy</td>
</tr>
<tr>
<td>Alberto Mantovani</td>
<td>University of Milan, Italy</td>
</tr>
<tr>
<td>Enzo Medico</td>
<td>University of Turin, Italy</td>
</tr>
<tr>
<td>Ignacio Melero Bermejo</td>
<td>University of Navarra, Pamplona, Spain</td>
</tr>
<tr>
<td>Davide Melisi</td>
<td>University of Verona, Italy</td>
</tr>
<tr>
<td>Delia Mezzanzanica</td>
<td>IRCCS National Cancer Institute, Milan, Italy</td>
</tr>
<tr>
<td>Andrea Necchi</td>
<td>IRCCS National Cancer Institute Milan, Italy</td>
</tr>
<tr>
<td>Paola Nisticò</td>
<td>Regina Elena National Cancer Institute, Rome, Italy</td>
</tr>
<tr>
<td>Nicola Normanno</td>
<td>National Cancer Institute “G. Pascale”, Naples, Italy</td>
</tr>
<tr>
<td>Ugo Pastorino</td>
<td>IRCCS National Cancer Institute, Milan, Italy</td>
</tr>
<tr>
<td>Solange Peters</td>
<td>Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland</td>
</tr>
<tr>
<td>Stefan Pfister</td>
<td>German Cancer Research Center, Heidelberg, Germany</td>
</tr>
<tr>
<td>Filippo Pietrantonio</td>
<td>IRCCS National Cancer Institute, Milan, Italy</td>
</tr>
<tr>
<td>Paolo Porporato</td>
<td>University of Turin, Italy</td>
</tr>
<tr>
<td>Maria Paula Roberti</td>
<td>Institute Gustave Roussy, Villejuif, France</td>
</tr>
<tr>
<td>Maurizio Scaltriti</td>
<td>Memorial Sloan Kettering Cancer Center, New York, USA</td>
</tr>
<tr>
<td>Katia Scotlandi</td>
<td>IRCCS Orthopaedic Rizzoli Institute, Bologna, Italy</td>
</tr>
<tr>
<td>Gabriella Sozzi</td>
<td>IRCCS National Cancer Institute, Milan, Italy</td>
</tr>
<tr>
<td>Andrea Speciale</td>
<td>University of Genoa, Italy</td>
</tr>
<tr>
<td>Lorenzo Stramucci</td>
<td>Regina Elena National Cancer Institute, Rome, Italy</td>
</tr>
<tr>
<td>Giulia Taraboletti</td>
<td>“Mario Negri” Institute for Pharmacological Research, Bergamo, Italy</td>
</tr>
<tr>
<td>Alice Turdo</td>
<td>University of Palermo, Italy</td>
</tr>
</tbody>
</table>
# Program at a Glance

## Wednesday, September 19th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00</td>
<td>Annual Meeting of SIC Young Investigators</td>
</tr>
<tr>
<td>13.30</td>
<td>Registration</td>
</tr>
<tr>
<td>14.00</td>
<td>Opening Address</td>
</tr>
<tr>
<td>15.00</td>
<td>Opening Lecture</td>
</tr>
<tr>
<td>16.00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>16.30</td>
<td><strong>LUNG CANCER</strong></td>
</tr>
<tr>
<td>19.00</td>
<td>Welcome Cocktail</td>
</tr>
</tbody>
</table>

## Thursday, September 20th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td><strong>BREAST CANCER</strong></td>
</tr>
<tr>
<td>10.00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10.30</td>
<td><strong>IMMUNOTHERAPY: PRECLINICAL &amp; CLINICAL</strong></td>
</tr>
<tr>
<td>12.00</td>
<td>Poster viewing with authors</td>
</tr>
<tr>
<td>13.00</td>
<td>Lunch</td>
</tr>
<tr>
<td>14.00</td>
<td><strong>POSTER DISCUSSION (4 PARALLEL SESSIONS)</strong></td>
</tr>
<tr>
<td>14.00</td>
<td>Poster Discussion 1A (Plenary Room)</td>
</tr>
<tr>
<td>14.00</td>
<td>Poster Discussion 1B (Workshop Room)</td>
</tr>
<tr>
<td>15.30</td>
<td>Poster Discussion 2A (Plenary Room)</td>
</tr>
<tr>
<td>15.30</td>
<td>Poster Discussion 2B (Workshop Room)</td>
</tr>
<tr>
<td>17.00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>17.30</td>
<td><strong>CHILDHOOD TUMORS</strong></td>
</tr>
</tbody>
</table>

## Friday, September 21st

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td><strong>COLON CANCER</strong></td>
</tr>
<tr>
<td>10.00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10.30</td>
<td><strong>MICROBIOME, METABOLISM &amp; CANCER</strong></td>
</tr>
<tr>
<td>12.00</td>
<td>Poster viewing with authors</td>
</tr>
<tr>
<td>13.00</td>
<td>Lunch</td>
</tr>
<tr>
<td>14.00</td>
<td>SIC meets Pharma Industry</td>
</tr>
<tr>
<td>16.00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>16.30</td>
<td><strong>Award ceremony</strong></td>
</tr>
<tr>
<td>17.30</td>
<td><strong>BIOMARKERS, NEW MOLECULAR TARGETS &amp; TARGETED THERAPIES</strong></td>
</tr>
<tr>
<td>19.00</td>
<td>SIC General Assembly</td>
</tr>
<tr>
<td>20.30</td>
<td>Social Event</td>
</tr>
</tbody>
</table>

## Saturday, September 22nd

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.45</td>
<td><strong>TUMOR MICROENVIRONMENT &amp; METASTASIS</strong></td>
</tr>
<tr>
<td>10.15</td>
<td>“Giorgio Prodi” lecture</td>
</tr>
<tr>
<td>11.15</td>
<td>Coffee break</td>
</tr>
<tr>
<td>11.45</td>
<td><strong>Award ceremony</strong></td>
</tr>
<tr>
<td>12.30</td>
<td>Closing lecture</td>
</tr>
<tr>
<td>13.30</td>
<td>Closing remarks</td>
</tr>
</tbody>
</table>
Scientific Program

Wednesday, September 19th

Plenary Room

10.00 - 12.30 Annual Meeting of SIC Young Investigators

13.30 Registration

Plenary Room

14.00 - 15.00 Opening Address
Greetings from the Authority

15.00 - 16.00 Opening Lecture
Hallmarks of Cancer: Applications for Cancer Medicine?
Douglas Hanahan, Lausanne (Switzerland)

16.00 - 16.30 Coffee Break

16.30 - 18.30 Lung Cancer
Chairs: Filippo De Braud, Milan (Italy) - Gabriella Sozzi, Milan (Italy)

CTC-Single cell analysis provides informative genetic profiles for lung cancer
Gerard Brady, Manchester (UK)

E13 Chemotherapy can promote metastasis outgrowth through recruitment of both metastasis initiating cells and myeloid-derived suppressor cells via the CXCL12/CXCR4 axis
G. Bertolini (IRCCS National Cancer Institute, Milan, Italy), V. Cancila, M. Tortoreto, G. Centonze, C. D’Alterio, S. Scala, C. Tripodo, G. Sozzi, L.Roz

Personalized prevention and screening of lung cancer
Ugo Pastorino, Milan (Italy)

C18 Investigating an aggressive molecular subtype of Stage I lung adenocarcinoma: evidences for the acquirement of a stem-like phenotype and immunoevasion
V. Melocchi, E. Dama, R. Cuttano, T. Colangelo, F. Bianchi (IRCCS-Casa Sollievo della Sofferenza - San Giovanni Rotondo, Italy)

Defining and optimizing the use of immunotherapy in NSCLC
Solange Peters, Lausanne (Switzerland)

19.00 Welcome Cocktail
Thursday, September 20th

**Plenary Room**

**8.30 - 10.00**

**Breast Cancer**

*Chairs: Massimo Di Nicola, Milan (Italy) - Serena Di Cosimo, Milan (Italy)*

Multilevel molecular analyses in breast cancer: gauging inter- and intra-tumor heterogeneity and elucidating its role in treatment response
Anne-Lise Børresen-Dale, Oslo (Norway)

B5 Insight into genetic susceptibility to BRCA-negative male breast cancer by multigene panel testing: results from a multicenter study in Italy

Translational research and neoadjuvant therapy of breast cancer: lessons learned and new perspectives
Luca Gianni, Milan (Italy)

P1 Bone marrow hematopoietic adaptation as a sensor of early, pre-invasive, mammary carcinoma
C. Chiodoni (IRCCS National Cancer Institute, Milan, Italy), V. Cancila, T.A. Renzi, A.M. Tomirotti, M. Perrone, M. Dugo, M. Milani, C. Tripodo, M.P. Colombo

**10.00 - 10.30** Coffee break

**10.30 - 12.00**

**Immunotherapy: preclinical & clinical**

*Chairs: Mario Paolo Colombo, Milan (Italy) - Marina Garassino, Milan (Italy)*

Innate Immunity, Inflammation and cancer: a double edged sword
Alberto Mantovani, Milan (Italy)

U5 Galectin-3 contributes to prostate cancer malignancy and immunosuppression in the early phases of disease development and metastasis
S. Caputo (San Raffaele Scientific Institute, Milan, Italy) M. Grioni, C. Brambillasca, E. Jachetti, M. Freschi, C. Doglioni, R. Galli, M. Bellone

Two pieces in the immunotherapy puzzle CD137 and IL-8
Ignacio Melero Bermejo, Pamplona (Spain)

U10 Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-Small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
M. Moro (IRCCS National Cancer Institute, Milan, Italy), G. Lo Russo, M. Sommariva, V. Cancila, M. Boeri, G. Centonze, M. Ganzinelli, M. Millione, G. Pruneri, C. Proto, S. Sangiulli, P. Gasparini, V. Torri, A. Anichini, L. Rivoltini, C. Tripodo, M.P. Colombo, A. Balsari, G. Sozzi, M.C. Garassino

**12.00 - 13.00** Poster viewing with authors

**13.00 - 14.00** Lunch

Poster Area
**Thursday, September 20th**

14.00-17.00 **POSTER DISCUSSION (4 PARALLEL SESSIONS)**

**Plenary Room**

14.00-15.30 **Poster Discussion 1A**

**Biomarkers and Therapy**

*Chairs: Marilena Iorio, Milan (Italy) - Alice Turdo, Palermo (Italy)*

**E2** *CD73: a new driver and a therapeutic target in ovarian cancer stem cells*
M. Lupia, K. Sachsenmeier, N. Colombo, F. Bianchi, U. Cavallaro *(European Institute of Oncology, Milan, Italy)*

**F9** *Identification of a novel miR-200b-c/ETAR/ZEB1 network involved in ovarian cancer progression*
R. Sestito *(IRCSS Regina Elena National Cancer Institute, Rome, Italy)*, L. Rosanò, R. Cianfrocca, P. Tocci, V. Di Castro, A. Sacconi, G. Blandino, A. Bagnato

**F11** *Plasma membrane-associated platforms to control tumor cell motility and invasion*
K. Sala *(Università Vita-Salute San Raffaele, Milan, Italy)*, A. Corbetta, D. Tonoli, C. Minici, M. Degano, E. Cammarota, D. Mazza, I. De Curtis

**K2** *Detection and monitoring of EWS-FLI1 fusion transcripts by liquid biopsy in ewing sarcoma patients*

**L2** *Coated Cationic Liposomes entrapping mir-660 inhibits tumor growth in Patients Derived Xenografts lung cancer models*
O. Fortunato *(IRCCS National Cancer Institute, Milan, Italy)*, M. Moro, D. Di Paolo, M. Milione, G. Centonze, V. Bornaghi, C. Borzi, P. Perri, U. Pastorino, M. Ponzoni G. Sozzi

**L11** *Targeting the pro-neoplastic role played by the chaperone TRAP1 in tumor cell mitochondria*
C. Sanchez-Martin, M. Ferraro, E. Moroni, I. Masgras, M. Serra, A. Columbano, G. Colombo, A. Rasola *(University of Padua, Italy)ova - Padova*

**Q9** *Identification of a 3-miRNAs signature in human osteosarcoma discriminating patient prognosis*
V. Chiadini *(IRCCS Orthopaedic Rizzoli Institute, Bologna, Italy)*, G. Romano, D. Veneziano, G. Nigita, P. Fadda, C.M. Croce, K. Scotlandi

**T1** *Analysis of cfDNA reveals high levels of tumor heterogeneity in NSCLC*
Cancer genetics, epigenetics and control of gene expression

**Chairs:** Tommaso Balestra, Bologna (Italy) - Marco Macagno, Turin (Italy)

**A2** Genetic inactivation of Nrf2 prevents clonal expansion of initiated cells in a nutritional model of rat hepatocarcinogenesis
C. Orrù (University of Cagliari, Italy), M. Szydlowska, K. Taguchi, P. Zavattari, A. Perra, M. Yamamoto, A. Columbano

**C12** Whole exome sequencing to discover lung tumor predisposition in women with previous breast cancer
S. Coco (“San Martino” Hospital, Genoa, Italy), S. Bonfiglio, D. Cittaro, C. Genova, I. Vanni, S. Boccardo, M. Mora, M.G. Dal Bello, E. Rijavec, A. Alama, A. Truini, V. Rossella, D. Lazarevic, A. Ballestrero, F. Grossi

**C20** Radiological and genomic evolution of individual metastasis during HER2 blockade in colorectal cancer

**C21** Identification of actionable cancer genes and treatment options for metastatic ovarian carcinomas using patient derived xenografts (PDXs) and PDX derived tumor cells (PDTcs)
C. D’Ambrosio (Candiolo Cancer Institute FPO-IRCCS, Candiolo, Italy), M. Olivero J. Erriquez, M. Arigoni, S. Capellero, G. Mittica, F. Borella, D. Katsaros, S. Privitera, E. Berrino, T. Venesio, G. Valabrega, R. Calogero, M.F. Di Renzo

**C23** Genetic Profiling of Malignant Pleural mesothelioma
F. Torricelli (IRCCS Reggio Emilia, Italy), F. Lococo, M. Pagano, R. Gnoni, G. Veronesi, O. Rena, C. Casadio, P. Novellis, S. Plana, B. Donati, T. Di Stefano, C. Pinto, A. Ciarrocchi

**H1** MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN amplified neuroblastoma
M. Petroni (Italian Technological Institute, Rome, Italy), F. Sardina, P. Infante, A. Bartolazzi, E. Locatelli, F. Fabretti, C. Capaldo, B. Cardinali, A. Coppa, V. Collicchia, M. Sahun Roncero, F. Belardinilli, L. Di Marcotullio, S. Soddu, M. Comes Franchini, E. Petricci, G. Gianninni

**K1** MYC-related micrornas signatures in non-hodgkin B-cell lymphomas and their relationships with core cellular pathways
G. Malpeli (University of Verona, Italy), S. Barbi, G. Tosadori, S. Greco, S. Zupo, S. Pedron, M. Brunelli, A. Bertolaso, M.T. Scupoli, P. Takam Kamga, M. Kramerpa, C. M. Croce, G.A. Calin, A. Scarpa, A. Zamò

**M3** A novel VEGFR2 mutation has oncogenic potential in braf wild-type melanoma
E. Grillo (University of the Study of Brescia, Italy), M. Di Somma, M. Corsini, C. Ravelli, L. Zammataro, M. Presta, S. Mitola
Thursday, September 20th

Plenary Room

15.30-17.00 Poster Discussion 2A

**Drug resistance, targeted therapy, cell metabolism**

*Chairs: Andrea Speciale, Genoa (Italy) - Lorenzo Stramucci, Rome (Italy)*

**D2** Combined positron emission tomography imaging approach for identification of new potential biomarker for treatment response in glioma models


**F15** Targeting semaphorin 4A-expressing myeloid cells to impair cancer progression

F. Maione *(Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy)* Y. Qiu, E. Garibaldi, A. Miranti, P. Gabriele, S. Brundu, E. Giraudo

**G1** Pik3c2g loss promotes pancreatic cancer through Mtor regulation and metabolic rewiring

M. Martini *(University of Turin, Italy)* M.C. De Santis, E. Ratto, L. Gozzelino, A. Derle, P.E. Porporato, E. Hirsch

**G8** Metastatic and metabolic features of patient-derived ovarian cancer xenografts

C. Ghilardi *(IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy)* A. Decio, L. Brunelli, M. Galimberti, R. Pastorelli, M.R. Bani, R. Giavazzi

**I4** A proteomic approach identified HSP90 as a central hub in CDDP-resistant ovarian cancer cells: role of HSP90 inhibitors in overcoming drug resistance


**I7** Genome scale CRISPR/Cas9 screen identifies Hippo pathway as key determinant for susceptibility to BET inhibitors in lung cancer

G. Gobbi, B. Donati, I.F. Do Valie, F. Reggiani, F. Torricelli, G. Castellani, D.C. Ambrosetti, A. Ciarrocchi, V. Sancisi *(IRCCS Reggio Emilia, Italy)*

**I11** MIR146A regulates melanoma sensitivity to BRAF/MEK inhibitors

E. Vergani, M. Dugo, C. Garigiuli, M. Cossa, F. Gallino, L. Di Guardo, F. Ferrarini, F. Ferrero, M. Sensi, L. Rivoltini, M. Rodolfo, V. Vallacchi *(IRCCS National Cancer Institute, Milan, Italy)*

**O3** MIR-506-RAD17 regulatory axis is a key node for synthetic lethal approaches targeting DNA repair pathway

R. Nicoletti, L. De Cecco, P. Alberti, F. Raspagliesi, E. Cecchin, D. Califano, S. Pignata, M. Bagnoli *(IRCCS National Cancer Institute, Milan, Italy)*, D. Mezzanzanica
Thursday, September 20th

Workshop Room

15.30-17.00  Poster Discussion 2B

Cancer stem cells, microenvironment, tumor immunology and microbiome  
**Chairs:** Antonino Bruno, Milan (Italy) - Federica Fusella, Turin (Italy)

**E1**  
WNT signaling modulates PD-L1 expression in stem cell compartment enhancing immune-evasion of triple negative breast cancer  

**E4**  
Chronic myeloid leukemia stem cells are sensitive to the pharmacological inhibition of ERK5 pathway  
E. Rovida (University of Florence, Italy), I. Tusa, G. Cheloni, A. Gozzini, X. Deng, N.S. Gray, S. Li, P. Dello Sbarba

**E5**  
Comparative transcriptomics of triple negative breast cancer stem cells and differentiated tumor cells identifies Teneurin-4 as a novel CSC-Associated molecule  
R. Ruiu (University of Turin, Italy), M. Arigoni, F. Riccardo, L. Conti, S. Lanzardo, R.A. Calogero, F. Cavallo, E. Quaglino

**J2**  
Antibiotics or probiotic aerosolization modulate pulmonary microbiota and promotes immunosurveillance against melanoma lung metastases  
V. Le Noci (IRCCS National Cancer Institute, Milan, Italy), S. Guglielmetti, S. Arioli C. Camisaschi, M. Sommariva, C. Storti, F. Bianchi, T. Triulzi, C. Castelli, A. Balsari, E. Tagliabue, L. Sfondrini

**U7**  
Newly developed CXCR4 antagonist potentiates T-cell trafficking and enhances PD-1 blockade efficacy in poor/high immunoresponsive mouse models  
C. D’Alterio (National Cancer Institute “G. Pascale”, Naples, Italy), M. Napolitano, L. Portella, G. Rea, A. Barbieri, A. Luciano, C. Arra, G. Scognamiglio, F. Tanganeto, A. Anniciello, M. Monaco, L. Gabriele, M. Buoncervello, G. Romagnoli, E. Cavaicenti, G. Botti, S. Scala, C. Ierano

**U3**  
Maternal immunization against ALK hinders tumor progression in neuroblastoma-prone offspring  
G. Barutello (University of Turin, Italy), F. Riccardo, C. Voena, E. Bolli, E. Quaglino, R. Chiaramonte, F. Cavallo

**V6**  
Breast cancer-adipocytes crosstalk as promoter of cancer progression  
I. Rybinska (IRCCS National Cancer Institute, Milan, Italy), V. Regondi, C. Ghirelli, E. Tagliabue, T. Triulzi

17.00 - 17.30  Coffee break

17.30 - 19.00  Childhood Tumors  
**Chairs:** Rita Falcioni, Rome (Italy) - Katia Scotlandi, Bologna (Italy)

New concepts for the diagnosis and treatment of childhood malignancies  
Stefan Pfister, Heidelberg (Germany)

**N4**  
Zyxin in ewing sarcoma: a novel role as mediator between CD99 and EWS-FLI1  
T. Balestra (IRCCS Orthopaedic Rizzoli Institute, Bologna, Italy), M.C. Manara, C. Garofalo, S. Santi, K. Scotlandi

Innovative approaches of immunotherapy to treat acute leukemias refractory to conventional therapies  
Franco Locatelli, Rome (Italy)

**N6**  
mRNA expression level of SRCIN1/p140CAP is an independent prognostic marker of outcome in neuroblastoma  
**Friday, September 21st**

### Plenary Room

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair(s)</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.30 - 10.00</td>
<td>Colon Cancer</td>
<td>Chairs: Davide Melisi, Verona (Italy) - Nicola Normanno, Naples (Italy)</td>
<td>Precision medicine in colorectal cancer&lt;br&gt;Roigero Dienstmann, Barcelona (Spain)</td>
</tr>
<tr>
<td></td>
<td>T3 Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies</td>
<td>G. Corti, M. Russo (Candiolo Cancer Institute - FPO - Candiolo, Italy), S. Lamba, A. Lorenzato, A. Sogari, G. Rospo, M. Montone, L. Lazzari, S. Arena, D. Oddo, M. Linnebacher, A. Sartore-Bianchi, F. Pietrantonio, S. Siena, F. Di Nicolantonio, A. Bardelli</td>
<td>Paolo Porporato, Turin (Italy)</td>
</tr>
<tr>
<td>10.00 - 10.30</td>
<td>Coffee break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30 - 12.00</td>
<td>Microbiome, metabolism &amp; cancer</td>
<td>Chairs: Paola Chiarugi, Florence (Italy) - Silvia Giordano, Turin (Italy)</td>
<td>Ileal Apoptosis and Microbiome Shape the Immunosurveillance and Prognosis of Proximal Colon Cancer&lt;br&gt;Maria Paula Roberti, Villejuif (France)</td>
</tr>
<tr>
<td></td>
<td>G7 Stromal contact regulates prostate cancer epigenetic and metabolic reprogramming</td>
<td>L. Ippolito (University of Florence, Italy) L. Ferrone, G. Comito, A. Morandi, E. Giannoni, P. Chiarugi</td>
<td>Metabolic control of tumor progression and cachexia&lt;br&gt;Paolo Porporato, Turin (Italy)</td>
</tr>
<tr>
<td></td>
<td>J1 Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression</td>
<td>A. Calcinozzo, A. Brevi (San Raffaele Scientific Institute, Milan, Italy) M. Chesi, R. Ferrarese, L. Garcia Perez, S. Kumar, K.J. Henderson, G. Tonon, M. Tomura, Y. Miwa, R.A. Flavell, S. Huber, F. Canducci, V.S. Rajkumar, P.L. Bergeagel, M. Bellone</td>
<td></td>
</tr>
<tr>
<td>12.00 - 13.00</td>
<td>Poster viewing with authors</td>
<td>Poster Area</td>
<td></td>
</tr>
<tr>
<td>13.00 - 14.00</td>
<td>Lunch</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Friday, September 21st

**Plenary Room**

**SIC meets Pharma Industry**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 - 14.30</td>
<td>Use of PI3K (fosfoinositide 3-chinasi) inhibitors in the clinic: ready for prime time? Maozrio Scaltriti, New York (USA)</td>
</tr>
<tr>
<td>14.30 - 15.00</td>
<td>Comprehensive Genomic Profile and F O ne to better select patients for clinical practice and research* Andrea Necchi, Milan (Italy)</td>
</tr>
<tr>
<td>15.00 - 15.30</td>
<td>The value of research for AstraZeneca’s Oncology* Constanza Oliveros, Milan (Italy) * Not accredited CME lecture</td>
</tr>
<tr>
<td>15.30 - 16.00</td>
<td>The EuROPDX EDIReX project: towards a European Research Infrastructure on patient-derived cancer models* Enzo Medico, Turin (Italy) * Not accredited CME lecture</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00 - 16.30</td>
<td>Coffee break</td>
</tr>
<tr>
<td>16.30 - 17.30</td>
<td>Award Ceremony</td>
</tr>
</tbody>
</table>

- “Elena Cappannini” award for the best 2017 publication
- “Pezcoller Foundation” Fellowship awards
- “Pezcoller Foundation - Ferruccio ed Elena Bernardi” Fellowship 2017-2018 Exploring new therapeutic approaches for pediatric Acute Myeloid Leukemia (AML): preclinical evaluation of a combined treatment with DOT1L and FLT3 inhibitors Annalisa Lonetti (University of Bologna, Italy)
- “Pezcoller Foundation - Alice Triangi” Fellowship 2017-2018 Prospective validation of a circulating microRNA signature classifier for early lung cancer detection: the BioMILD trial Mattia Boeri (IRCCS National Cancer Institute, Milan, Italy)
- “Pezcoller Foundation - Ferruccio ed Elena Bernardi” Fellowship award 2019-2020
- “Pezcoller Foundation - Alice Triangi” Fellowship award 2019-2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.30 - 19.00</td>
<td>Biomarkers, new molecular targets &amp; targeted therapies Chairs: Amedeo Columbano, Cagliari (Italy) - Delia Mezzanzanica, Milan (Italy)</td>
</tr>
</tbody>
</table>

- Mutant p53 at the crossroads of mechano-signalling and metabolic pathways in cancer Giannino Del Sal, Trieste (Italy)
- Quantitative mapping of epigenetic marks by MS-proteomics in breast cancer samples, for patient stratification and discovery of new therapeutic targets T. Bonaldi (European Institute of Oncology, Milan, Italy), R. Noberini
- Role of parp inhibitor in the ovarian cancer treatment Domenica Lorusso, Milan (Italy)
- Palbociclib, a CDK4/6 inhibitor, as a new strategy of treatment in triple negative breast cancer, malignant pleural mesothelioma, and hepatocellular carcinoma D. Cretella (University of Parma, Italy), M. Bonelli, G. Digiacomo, C. Fumarola, A. Ravelli, P.G. Petronini

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>19.00 - 20.00</td>
<td>SIC General Assembly</td>
</tr>
</tbody>
</table>
### Saturday, September 22nd

**Plenary Room**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 8.45 - 10.15 | **Tumor microenvironment & metastasis**  
*Chairs: Andrea Anichini, Milan (Italy) - Giulia Taraboletti, Bergamo (Italy)*  
HMena splicing, a key mediator of pro-invasive stroma: a useful candidate for deciphering the tumor microenvironment?  
Paola Nisticò, Rome (Italy)  
**V14** Inhibition of EXPORTIN-1 (XPO1) activity reverses pro-tumorigenic secretory phenotype of lung cancer fibroblasts  
A. Bruccoleri, F. Andriani, F. Facchinetti, O. Rondinone, U. Pastorino, G. Sozzi, L. Roz  
(IRCCS, National Cancer Institute, Milan, Italy)  
Perivascular regulation of tumor dormancy and drug resistance  
Cyrus Ghajar, Seattle (USA) |  
| 10.15 - 11.15 | **“Giorgio Prodi” Lecture**  
Targeting invasion, angiogenesis and the tumor microenvironment: from therapy to cancer prevention  
Adriana Albini, Milan (Italy) |
| 11.15 - 11.45 | Coffee break |  
| 11.45 - 12.30 | **Award Ceremony**  
“Piero Trivella” Award for the Best Posters |  
| 12.30 - 13.30 | **Closing Lecture**  
Inactivation of DNA repair to improve cancer immune surveillance  
Alberto Bardelli, Turin (Italy) |  
| 13.30 | Closing remarks |
Scientific Information

CME CREDITS
No. 5,4 Italian Ministry of Health for the following Professions and Disciplines: Medical Surgeon (Disciplines: Haematology, General (Family Doctors) Medicine, Medical Genetics, Oncology, Pathological Anatomy, Pharmacology and Clinical Toxicology, Clinical Pathology, Internal Medicine); Biologist, Pharmacist, Chemist (Discipline: Analytical Chemistry); Physicist (Discipline: Health Physics); Veterinary Surgeon.

SLIDES
Slides must be in English. Computer videoprojection will be available in Power Point. Please communicate to the Organizing Secretariat your different requirements as soon as possible. Slides have to be handed to the slide centre one hour before the session beginning.

PRIZES
Friday, September 21st
“Pezcolle Foundation” Fellowship 2017-2018:
Winner award - Annalisa Lonetti, Bologna (Italy)
Winner award - Mattia Boeri, Milan (Italy)
“Pezcolle Foundation” Fellowship 2019-2020
“Elena Cappannini” award for the best 2017 publication

Saturday, September 22nd
“Piero Trivella” Award for the Best Posters

General Information

CONGRESS VENUE
Università degli Studi di Milano
Via Festa del Perdono 7
20122 Milano

How to reach the Congress Venue

Linate Airport is about 10 km from Milan city centre. Take bus No. 73 to the city centre and get off at Via Larga, a few minutes walk from the Università degli Studi di Milano.

Malpensa Airport is about 50 km from Milan city centre. There are links to Cadorna Railway Station by Malpensa Express train and to the Central Station by bus. Once you are at Cadorna station take the Red Line Subway (MM1) (direction Sesto FS) and get off at Piazza Duomo, a few minutes walk from the Università degli Studi di Milano or Bus 94 (direction P.ta Nuova) and get off at Via Francesco Sforza-Policlinico, a few minutes walk from the Università degli Studi di Milano.

Milan Central Station (Stazione Centrale). Take the Yellow Line Subway (MM3) (direction San Donato) and get off at Missori-Università degli Studi, a few minutes walk from the Università degli Studi di Milano.

Public Transportation. Very close by are the bus stops (54, 60, 73, 84, 94) of the trams (12,14,15, 16, 23, 24, 27) and subways MM1-Red and MM3-Yellow. For further information about the ticket purchase please visit the website www.atm.it.

By private car: The Congress venue (Università degli Studi di Milano, in Via Festa del Perdono 7) is located within a restricted traffic zone (ZTL Area C).

To enter “Area C” you are required to purchase and activate an entrance ticket. The ticket costs 5 euro and must be activated no later than midnight of the day after you access the restricted area.

It can be purchased at the parking meters, newsagents, tobacconists, ATM points (Milan Transport Company), ATMs of Intesa Sanpaolo, by visiting the website www.areac.atm-mi.it, calling the call center at the number + 39.02.48684001 or sending a SMS to 48444

The nearest car park is the Car Central Parking - Duomo di Milano in Via Chiaravalle 12
General Information

OFFICIAL LANGUAGE
English. Simultaneous translation will not be provided.

BADGE
Participants and exhibitors are kindly requested to wear their badge during the congress.

CERTIFICATE OF ATTENDANCE
Certificate of attendance is given to all registered participants at the end of the congress.

EXHIBITION AND SPONSORSHIP
A technical, pharmaceutical and publication exhibition will be held in the Congress Venue. For any information please contact the Organizing Secretariat.

REGISTRATION FEE

<table>
<thead>
<tr>
<th></th>
<th>On site</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIC MEMBER</td>
<td>€ 450,00*</td>
</tr>
<tr>
<td>NON SIC MEMBER</td>
<td>€ 550,00**</td>
</tr>
<tr>
<td>SIC MEMBER UNDER 35</td>
<td>€ 280,00*</td>
</tr>
<tr>
<td>NON SIC MEMBER UNDER 35</td>
<td>€ 335,00**</td>
</tr>
</tbody>
</table>

(*)VAT non applicable as for law ex Art.4 DPR 633/72;  (***) VAT included

The VAT rate will be applied depending on the Italian fiscal law at the time of payment.

Registration fees include:
- admission to the scientific sessions
- admission to the exhibition area
- name badge and congress kit
- abstracts book
- attendance certificate
- CME certificate
- welcome cocktail, coffee breaks, light lunches and social dinner

PAYMENT
Payment on site: by cash or credit card (accepted VISA and MASTERCARD).

CANCELLATION
In case of cancellation no reimbursement is foreseen.
Thanks to
60th Annual Meeting of the Italian Cancer Society
Care and cure of cancer patients: bridging basic research into clinical setting

Milan, 19 - 22 September 2018
Università Privata Statale
Via Festa dei Perdono, 7

SIC Secretariat
Società Italiana di Cancerologia
Via G. Venezian, 1
20133 Milano MI
E-mail: sic@istitutotumori.mi.it
www.cancerologia.it

Organizing Secretariat
Via Sassonia, 30
47922 Rimini RN
E-mail: sic2018@adriacongrex.it
www.adriacongrex.it